Jay Penney

Jay Penney

Auto-generated profile, based on publicly available information

Jay Penney

Department of Biomedical Sciences, AVC, University of Prince Edward Island, Charlottetown, Canada

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2023 in Glia
Verified
Journal Article
Open access
JPJay Penney
Jay Penney
WRWilliam T. Ralvenius
William T. Ralvenius
ALAnjanet Loon
Anjanet Loon
OCOyku Cerit
Oyku Cerit
VDVishnu Dileep
Vishnu Dileep
LTLi‐Huei Tsai
Li‐Huei Tsai
Genetic findings have highlighted key roles for microglia in the pathology of neurodegenerative conditions such as Alzheimer's disease (AD). A number of mutations in the microglial protein triggering receptor expressed on myeloid cells 2 (TREM2) have been associated with increased risk for developing AD, most notably the R47H/+ substitution. We employed gene editing and stem cell models to gain insight into the effects of the TREM2 R47H/+ mutation on human‐induced pluripotent stem cell‐derived microglia. We found transcriptional changes affecting numerous cellular processes, with R47H/+ cells exhibiting a proinflammatory gene expression signature. TREM2 R47H/+ also caused impairments in microglial movement and the uptake of multiple substrates, as well as rendering microglia hyperresponsive to inflammatory stimuli. We developed an in vitro laser‐induced injury model in neuron–microglia cocultures, finding an impaired injury response by TREM2 R47H/+ microglia. Furthermore, mouse brains transplanted with TREM2 R47H/+ microglia exhibited reduced synaptic density, with upregulation of multiple complement cascade components in TREM2 R47H/+ microglia suggesting inappropriate synaptic pruning as one potential mechanism. These findings identify a number of potentially detrimental effects of the TREM2 R47H/+ mutation on microglial gene expression and function likely to underlie its association with AD.

1 November 2024 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
ATAlex R. Trainor
Alex R. Trainor
DMDebra S. MacDonald
Debra S. MacDonald
JPJay Penney
Jay Penney
The prevalence of neurodegenerative disorders such as Parkinson’s disease are increasing as world populations age. Despite this growing public health concern, the precise molecular and cellular mechanisms that culminate in neurodegeneration remain unclear. Effective treatment options for Parkinson’s disease and other neurodegenerative disorders remain very limited, due in part to this uncertain disease etiology. One commonality across neurodegenerative diseases is sustained neuroinflammation, mediated in large part by microglia, the innate immune cells of the brain. Initially thought to simply react to neuron-derived pathology, genetic and functional studies in recent years suggest that microglia play a more active role in the neurodegenerative process than previously appreciated. Here, we review evidence for the roles of microglia in Parkinson’s disease pathogenesis and progression, with a particular focus on microglial functions that are perturbed by disease associated genes and mutations.

29 August 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
WRWilliam T. Ralvenius
William T. Ralvenius
AMAlison E. Mungenast
Alison E. Mungenast
HWHannah Woolf
Hannah Woolf
MHMargaret M. Huston
Margaret M. Huston
TGTyler Z. Gillingham
Tyler Z. Gillingham
LTLi-Huei Tsai
Li-Huei Tsai
Pervasive neuroinflammation occurs in many neurodegenerative diseases, including Alzheimer’s disease (AD). SPI1/PU.1 is a transcription factor located at a genome-wide significant AD-risk locus and its reduced expression is associated with delayed onset of AD. We analyzed single-cell transcriptomic datasets from microglia of human AD patients and found an enrichment of PU.1-binding motifs in the differentially expressed genes. In hippocampal tissues from transgenic mice with neurodegeneration, we found vastly increased genomic PU.1 binding. We then screened for PU.1 inhibitors using a PU.1 reporter cell line and discovered A11, a molecule with anti-inflammatory efficacy and nanomolar potency. A11 regulated genes putatively by recruiting a repressive complex containing MECP2, HDAC1, SIN3A, and DNMT3A to PU.1 motifs, thus representing a novel mechanism and class of molecules. In mouse models of AD, A11 ameliorated neuroinflammation, loss of neuronal integrity, AD pathology, and improved cognitive performance. This study uncovers a novel class of anti-inflammatory molecules with therapeutic potential for neurodegenerative disorders.

26 June 2024 in Neural Regeneration Research
Verified
Journal Article
Open access
DMDebra S. MacDonald
Debra S. MacDonald
JPJay Penney
Jay Penney

6 October 2026 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
QTQuang Nang Truong
Quang Nang Truong
ATAlex R. Trainor
Alex R. Trainor
JPJay Penney
Jay Penney